解決FSHD

2023年4月18日

舊金山,加利福尼亞,美國南部舊金山,加利福尼亞州,4月18日,2023(全球通訊社)——史詩般的生物,生物科技公司發展療法使用緊湊的調節基因表達,non-cutting dca蛋白質,由解決FSHD今天宣布了一項投資,風險慈善組織,支持史詩生物程序epi - 321治療facioscapulohumeral肌肉萎縮症(FSHD)。Facioscapulohumeral肌肉萎縮症是最常見的一種形式的成人肌肉萎縮症,影響worldwide1 1 8000人,2。症狀通常開始在20歲之前,可能導致患者被50歲坐在輪椅上。FSHD沒有治療方案,患者症狀管理通過使用輔助設備,物理治療、骨科。“我們非常感激的支持為我們的工作發展解決FSHD首開先河的方法治療FSHD調節基因活性。他們的投資代表不僅僅是一個財務貢獻也驗證我們的使命,我們的團隊致力於養護這虛弱的疾病。這項投資,我們正準備與解決FSHD密切合作,讓我們追求有意義的進步改善FSHD受災民眾的生活,“琥珀Salzman說,博士,首席執行官史詩般的生物。“我們很高興看到史詩生物的優先級FSHD作為他們的領導指示,鑒於迫切需要治療這種疾病。我們一直印象深刻的巨大功能基因表達調製係統(寶石),提供了潛在的抑製病理基礎FSHD外遺傳性事件。我們感到興奮與史詩生物團隊工作在這一潛在變革性治療病人,”伊娃的下巴說,博士,解決FSHD執行主任。 "I am hopeful that Epic Bio's research will lead to breakthroughs in the treatment of FSHD and, ultimately, a cure. We need to keep pushing the boundaries of science and technology to find solutions for those of us living with this disease," added Chip Wilson, founder and chairman of the Board of SOLVE FSHD. About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, widely known as the founder and part owner of various technical apparel companies including lululemon and Amer Sports, which holds brands such as Arc’teryx, Salomon and Wilson Sports. Chip has committed $100 million to kick-start funding into projects that support the organization’s mission to find a cure for FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD. If you are interested in working with SOLVE FSHD, contact info@solvefshd.com. If you have FSHD and want to find out about clinical trials or be included in the FSHD registry, please see Solve FSHD’s website - https://solvefshd.com/ About Epic Bio Epic Bio is a leading epigenome engineering company, leveraging the power of CRISPR without cutting DNA. The company is using its proprietary Gene Expression Modulation System (GEMS) to develop therapies. Through the company’s library of the most compact Cas DNA-binding proteins to work on human cells, the company is developing in vivo therapies with delivery via a single AAV vector. Epic Bio has an initial focus on Facioscapulohumeral Muscular Dystrophy (FSHD) and is conducting additional research to address Antitrypsin Deficiency (A1AD), Heterozygous Familial Hypocholesterolemia (HeFH), as well as other indications. The company is financially backed by Horizons Ventures and other leading investors. Visit www.epic-bio.com for more information or follow us on Twitter and LinkedIn . 1 Cohen J, et al. Trends Mol Med. 2021 Feb; 27(2):123-137 2 Schatzl T, et al. Orphanet J Rare Dis. 2021 Mar; 16(129) Investor Contact